# MediLedger: Blockchain-based Pharmaceutical Traceability

> MediLedger is an industry-led blockchain project that improves the traceability and authenticity of pharmaceuticals in the supply chain from manufacturer to dispenser. The system reduces verification time for returned medications from up to 48 hours to less than 400 milliseconds and supports compliance with the Drug Supply Chain Security Act (DSCSA). Since 2019, the network has been commercially operational and was successfully tested in a comprehensive FDA pilot project in 2023.

**Sector:** Tertiary sector · **Industry:** Pharmaceutical sales and services · **Organisation:** MediLedger · **Maturity level:** Production

Canonical URL: https://www.sapientblock.com/en/use-cases/mediledger-pharmalieferkette-lueckenlos-sichern

## Documentation status

- **Project status:** Production
- **Evidence:** Evidence high
- **Editorial review:** Ufuk Avci, 15 April 2026

## Description

MediLedger is a Hyperledger Fabric-based blockchain platform for DSCSA compliance, developed by Chronicled (San Francisco). The FDA pilot report (available on fda.gov) documents the technical architecture in detail: each medication unit is managed as a non-fungible token; ownership changes via smart contract; zk-SNARKs protect proprietary pricing data.

The DSCSA (Drug Supply Chain Security Act, 2013) mandates phased full serialization and interoperable traceability of all US prescription drugs. Full compliance became mandatory in November 2023. MediLedger architecture: each package receives a serial number; upon shipping, the manufacturer creates a blockchain entry (EPCIS standard); each ownership change (manufacturer→wholesaler→pharmacy) is documented as a smart contract transaction. zk-SNARKs (Zero-Knowledge Succinct Non-Interactive Arguments of Knowledge): compliance checks can be performed without revealing price negotiation or quantity data. Performance test in the FDA pilot: 2,000 transactions per second achieved — sufficient for the US pharmaceutical industry. Ledger Insights was the first media outlet to report extensively on the FDA MediLedger pilot. NCBI/PMC publication: scientific validation of blockchain-based drug traceability.

## Benefits

- Companies achieve cost savings through more efficient system operations and automated DSCSA compliance processes.
- Verification time for returned medications is reduced from up to 48 hours to less than 400 milliseconds.
- The system simplifies chargeback processes and optimises the entire supply chain through automated compliance adherence.
- Blockchain technology provides immutable records and increases transparency in the pharmaceutical supply chain.
- Employees can complete verification processes significantly faster and have more time for patient-focused activities.

## Challenges

- Companies must adapt their existing processes and invest in new barcode scanners and software integrations.
- Implementation requires comprehensive coordination among all supply chain actors from manufacturers to pharmacies.
- Integration with existing legacy systems and ERP software poses high technical demands on IT infrastructure.
- Employees need training for the new blockchain-based verification systems and scanner technologies.

## Technology foundation

MediLedger uses a decentralised blockchain network specifically developed for the needs of the pharmaceutical industry. Blockchain technology enables the creation of an immutable and transparent record of all medication transactions, thereby verifying product authenticity and preventing counterfeiting.

## Sources

- [FDA Blockchain Pilot MediLedger](https://www.ledgerinsights.com/fda-blockchain-pilot-mediledger/)
- [MediLedger Supply Chain Pharmaindustrie](https://blockchainwelt.de/mediledger-supply-chain-pharmaindustrie/)
- [Blockchain-enabled drug traceability](https://pmc.ncbi.nlm.nih.gov/articles/PMC11073477/)
- [FDA Pilot Program Report](https://www.fda.gov/media/168283/download)